Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.66 |
| ▸ | CA12 | O43570 | 2/20 | 0.57 |
| ▸ | CA9 | Q16790 | 2/20 | 0.57 |
| ▸ | FASN | P49327 | 1/20 | 0.56 |
| ▸ | CTSV | O60911 | 1/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.51 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.51 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.51 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.51 |
| ▸ | TNKS | O95271 | 1/20 | 0.49 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | GABRP | O00591 | 1/20 | 0.48 |
| ▸ | GABRD | O14764 | 1/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7251935 | 0.85 | PARP1 (0.68) | PARP1CA12CA9FASNCTSV | |
| SCHEMBL7251641 | 0.84 | PARP1 (0.66) | PARP1CA12CA9FASNCTSV | |
| SCHEMBL7256590 | 0.84 | PARP1 (0.66) | PARP1CA12CA9FASNCTSV | |
| SCHEMBL7251898 | 0.84 | PARP1 (0.66) | PARP1CA12CA9FASNCTSV | |
| SCHEMBL899132 | 0.80 | PARP1 (1.00) | PARP1CA12CA9FASNCTSV | |
| SCHEMBL7585508 | 0.77 | PARP1 (0.62) | PARP1CA12CA9TNKSTNKS2 | |
| SCHEMBL9389021 | 0.77 | PARP1 (0.60) | PARP1CA12CA9FASNCTSV | |
| SCHEMBL7250753 | 0.77 | KDM4E (0.52) | PARP1CA12CA9TNKSTNKS2 | |
| SCHEMBL11365834 | 0.77 | PARP1 (0.72) | PARP1CA12CA9FASNCTSV | |
| SCHEMBL8895896 | 0.74 | GRIN2D (0.66) | PARP1CA12CA9FASNCTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030105102-A1 | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting PARP activity | GUILFORD PHARMACEUTICALS INC. | 2003-06-05 | — | — | US | claimed |
| US-20020022636-A1 | OXO-SUBSTITUTED COMPOUNDS, PROCESS OF MAKING, AND COMPOSITIONS AND METHODS FOR INHIBITING PARP ACTIVITY | GUILFORD PHARMACEUTICALS INC. | 2002-02-21 | — | — | US | claimed |
| EP-1009739-A2 | OXO-SUBSTITUTED COMPOUNDS, PROCESS OF MAKING, AND COMPOSITIONS AND METHODS FOR INHIBITING PARP ACTIVITY | GUILFORD PHARMACEUTICALS INC. (US) | 2000-06-21 | — | — | EP | claimed |
| WO-1999011624-A1 | OXO-SUBSTITUTED COMPOUNDS, PROCESS OF MAKING, AND COMPOSITIONS AND METHODS FOR INHIBITING PARP ACTIVITY | GUILFORD PHARMACEUTICALS INC. (US) | 1999-03-11 | — | — | WO | claimed |
| US-6235748-B1 | CENTRAL NERVOUS SYSTEM DISORDERS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2001-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022636-A1 | OXO-SUBSTITUTED COMPOUNDS, PROCESS OF MAKING, AND COMPOSITIONS AND METHODS FOR INHIBITING PARP ACTIVITY | PARP2, PARP1, PARP3 | PARP1 2/4885CA12 1479/4885CA9 229/4885 |
| US-20030105102-A1 | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting PARP activity | PARP1, PARP3, PARP2 | PARP1 1/4885CA12 1774/4885CA9 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.